FindTrial
Sign In

The Safety and Efficacy of Fecal Microbiota Transplantation in the Treatment of Digestive Diseases and Non-digestive System Diseases Associated With Gastrointestinal Symptoms in the Gastrointestinal Tract.

The Safety and Efficacy of Fecal Microbiota Transplantation in the Treatment of Digestive Diseases and Non-digestive System Diseases Associated With Gastrointestinal Symptoms in the Gastrointestinal Tract.

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06208930
Enrollment
10000
Registered
2024-01-17
Start date
2018-01-10
Completion date
2025-12-10
Last updated
2024-01-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fecal Microbiota Transplantation

Brief summary

The exploration of the safety and efficacy of fecal microbiota transplantation in the treatment of non-digestive system diseases associated with gastrointestinal symptoms in the gastrointestinal tract, while also investigating the impact of fecal microbiota transplantation on the intestinal system, and assessing the improvement of symptoms in other systems.Simultaneously optimizing the conditions during the FMT process, identifying the most effective treatment methods to enhance the therapeutic outcomes of FMT.

Interventions

PROCEDUREFecal microbiota transplantation

Fecal microbiota transplantation (FMT) is a method for treating imbalances in the intestinal microbiota. Its basic principle involves extracting a portion of feces from a healthy individual that contains a diverse population of beneficial bacteria, processing it, and transplanting it into the digestive system of the recipient to restore a balanced intestinal microbiota.

Sponsors

Shanghai 10th People's Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Being able to tolerate a nasoenteric tube or swallow a capsule.

Exclusion criteria

* Intestinal barrier dysfunction. Inability to tolerate enteral nutrition.

Design outcomes

Primary

MeasureTime frameDescription
Comparing the therapeutic efficacy of patients after FMT.0day, 7days, 30days, 3 months, 6months,12 monthsThrough conducting relevant questionnaire surveys with patients, we can gain insights into the therapeutic efficacy of patients after undergoing FMT.
Comparing the differences in microbiota composition in samples such as feces and small intestinal fluid from patients.0day, 7days, 30days, 3 months, 6months,12 monthsPerforming 16S rRNA sequencing, metagenomic sequencing, and metabolite analysis on the samples.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026